-$0.01 Earnings Per Share Expected for Isoray, Inc. (NYSE:ISR) This Quarter

Wall Street analysts expect Isoray, Inc. (NYSE:ISRGet Rating) to report earnings per share (EPS) of ($0.01) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Isoray’s earnings. The lowest EPS estimate is ($0.01) and the highest is $0.00. Isoray also reported earnings of ($0.01) per share in the same quarter last year. The firm is expected to report its next earnings results on Monday, January 1st.

On average, analysts expect that Isoray will report full year earnings of ($0.05) per share for the current financial year, with EPS estimates ranging from ($0.05) to ($0.04). For the next fiscal year, analysts forecast that the company will post earnings of ($0.02) per share, with EPS estimates ranging from ($0.05) to $0.02. Zacks’ earnings per share calculations are an average based on a survey of research firms that cover Isoray.

Separately, StockNews.com initiated coverage on Isoray in a report on Saturday. They issued a “sell” rating on the stock.

Shares of ISR traded up $0.00 during trading hours on Wednesday, reaching $0.29. The stock had a trading volume of 900 shares, compared to its average volume of 411,413. Isoray has a 12 month low of $0.25 and a 12 month high of $0.94. The stock’s 50-day moving average is $0.33. The firm has a market cap of $41.45 million, a P/E ratio of -5.84 and a beta of 1.02.

About Isoray (Get Rating)

Isoray, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers.

Recommended Stories

Get a free copy of the Zacks research report on Isoray (ISR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Isoray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isoray and related companies with MarketBeat.com's FREE daily email newsletter.